WO2002055019A3 - Methods for ameliorating childhood infections - Google Patents

Methods for ameliorating childhood infections Download PDF

Info

Publication number
WO2002055019A3
WO2002055019A3 PCT/US2001/045244 US0145244W WO02055019A3 WO 2002055019 A3 WO2002055019 A3 WO 2002055019A3 US 0145244 W US0145244 W US 0145244W WO 02055019 A3 WO02055019 A3 WO 02055019A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
ameliorating
childhood infections
childhood
infections
Prior art date
Application number
PCT/US2001/045244
Other languages
French (fr)
Other versions
WO2002055019A2 (en
Inventor
Michael J Holtzman
Original Assignee
Univ Washington
Michael J Holtzman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Michael J Holtzman filed Critical Univ Washington
Priority to AU2002243260A priority Critical patent/AU2002243260A1/en
Priority to US10/416,938 priority patent/US20040116341A1/en
Priority to EP01989144A priority patent/EP1349566A4/en
Publication of WO2002055019A2 publication Critical patent/WO2002055019A2/en
Publication of WO2002055019A3 publication Critical patent/WO2002055019A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods to treat paramyxovirus infection are disclosed, which comprise administering RANTES protein or an expression system therefor. Also discloses are methods to identify individuals susceptible to paramyxovirus infection.
PCT/US2001/045244 2000-10-24 2001-10-23 Methods for ameliorating childhood infections WO2002055019A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002243260A AU2002243260A1 (en) 2000-10-24 2001-10-23 Methods for ameliorating childhood infections
US10/416,938 US20040116341A1 (en) 2001-10-23 2001-10-23 Methods for ameliorating childhood infections
EP01989144A EP1349566A4 (en) 2000-10-24 2001-10-23 Methods for ameliorating childhood infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24326400P 2000-10-24 2000-10-24
US60/243,264 2000-10-24

Publications (2)

Publication Number Publication Date
WO2002055019A2 WO2002055019A2 (en) 2002-07-18
WO2002055019A3 true WO2002055019A3 (en) 2002-09-26

Family

ID=22918007

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/045244 WO2002055019A2 (en) 2000-10-24 2001-10-23 Methods for ameliorating childhood infections

Country Status (3)

Country Link
EP (1) EP1349566A4 (en)
AU (1) AU2002243260A1 (en)
WO (1) WO2002055019A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0417937A (en) * 2003-12-30 2007-04-17 Wyeth Corp antiviral composition; recombinant expression vector; transfected, transformed or vector-infected host cell; recombinant expression vector; small mimetic organic molecule; and mimetic nh2 termination peptide of a ccl5 polypeptide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062535A2 (en) * 1998-06-01 1999-12-09 University Of Maryland Biotechnology Institute Receptor ligand antagonist complexes and their use in treating or preventing receptor mediated diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087066A1 (en) * 2000-05-12 2001-11-22 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062535A2 (en) * 1998-06-01 1999-12-09 University Of Maryland Biotechnology Institute Receptor ligand antagonist complexes and their use in treating or preventing receptor mediated diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1349566A4 *
STUMBLES P.A. ET AL.: "Regulation of dendritic cell recruitment into resting and inflamed airway epithelium: Use of alternative chemokine receptors as a function of inducing stimulus", JOURNAL OF IMMUNOLOGY, vol. 167, no. 1, July 2001 (2001-07-01), pages 228 - 234, XP002951609 *

Also Published As

Publication number Publication date
WO2002055019A2 (en) 2002-07-18
AU2002243260A1 (en) 2002-07-24
EP1349566A2 (en) 2003-10-08
EP1349566A4 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
AU5782900A (en) Secure, limited-access database system and method
WO2005002526A3 (en) Method and compositions for treatment of viral infections
AU2001266188A1 (en) Database system, particularly for multimedia objects
AU2002318165A1 (en) Fingerprint recognition system
AU2002230766A1 (en) System, process and software arrangement for recognizing handwritten characters
WO2002050061A8 (en) Piperazine derivatives for treatment of bacterial infections
HK1037248A1 (en) Method of executing microprocessor instructions, associated microprocessor and data processing system.
WO2004007743A3 (en) Use of cpg nucleic acids in prion-disease
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
WO2004035169A3 (en) Multidimensional protein separation system
WO1999063978A3 (en) Methods of treating microbial infection and therapeutic formulations therefor
PT932613E (en) EXPRESSION OF BLOCKING VIRULENCE FACTS IN S. AUREUS
WO2006076504A3 (en) Sialic acid permease system
MY141820A (en) A system and associated method to determine authentication priority between devices
WO2002055019A3 (en) Methods for ameliorating childhood infections
WO2002094881A3 (en) Monoclonal antibody neutralising cathepsin b activity and uses thereof
WO2002044384A3 (en) T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy
MXPA04002103A (en) A caspase- 8 binding protein, its preparation and use.
AU2001242824A1 (en) Individual body identifying method by two-dimensional code, hybrid individual person authenticating system, and off-line person identifying system
WO2003004650A3 (en) Group b streptococcus antigens and corresponding dna fragments
WO2004075028A3 (en) Systems and methods for variable rebate and incentive programs
WO2003022883A3 (en) Use of proteins for the production of a medicament for stimulating the innate non specific immune system
WO2004020466A8 (en) Protein tyrosine phosphatase inhibitors
NO20020064D0 (en) Chlamysin B antibacterial protein, gene encoding this as well as an expression system for this
WO1999053091A3 (en) Dna coding for gdnf, parts of said dna and gdnf variants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001989144

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001989144

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10416938

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001989144

Country of ref document: EP